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had a BNP level > 100 during that time frame (Odds ratio
10.8, 95% CI (1.3 e 91.5)). Six patients (12%) died due to
transplant related mortality in the ﬁrst 100 days; 5 of these
(83%) had a BNP level >100 during the ﬁrst 14 days.
Conclusions: BNP levels peaked at Day +14 after allogeneic
HSCT in this study. Children who required critical care
resources (oxygen and PICU admission) almost invariably
demonstrated an elevated BNP during the ﬁrst 14 days after
HSCT. This information may be useful clinically and for risk
stratiﬁcation in studies of pediatric HSCT patients. The
etiology of the rise in BNP requires further study.Table 1
Patient Characteristics (n¼32)
Characteristic N (%)
Median age (range) 48 (20-62)
Diagnosis
AML/ALL/MDS/CML 3/5/7/3
CLL/NHL/Myeloma 2/6/4
Other 2
Donor source
Matched sibling 15 (47)
Matched unrelated 13 (41)
Mismatched unrelated / haploidentical / cord blood 4 (12)
Conditioning regimen
Myeloablative 19 (59)
Reduced intensity 13 (41)
Acute GVHD 14 (44)
Chronic GVHD 27 (84)
Patients on2 immunosuppressors at RSV diagnosis 21 (66)
Clinical syndrome
Upper tract infection 16 (50)
Pneumonia 16 (50)
Median days from transplant to RSV infection
(interquartile range)
382 (241 to 1049)292
Research qPCR Method for Engraftment Monitoring: A
6-Year Review of Proﬁciency Testing Results
Ian J. McLaughlin, Christopher L. Sigua, Douglas A. Bost. Quest
Diagnostics
A total of 40 samples were tested from 11 proﬁciency surveys
from 2006 through 2012 using samples from the American
Society for Histocompatibility and Immunogenetics (ASHI)
and the Post-SCT Chimerism Monitoring Programme of the
United Kingdom National External Quality Assessment
Schemes (UK NEQAS) for Leucocyte Immunophenotyping.
Sample percentage breakdown by reported means for the 39
ASHI samples is as follows: 3 did not consist of target cells
(0% samples), 5 consisted of target percentages from 5.7 to
22.28%, 8 consisted of target percentages from 26.2 to 49.2%,
20 consisted of target percentages from 51.2 to 95.93%, and 3
consisted only of target cells (100% samples). The single UK
NEQAS sample reported a median percentage of 94.70%.
Thirty-two of the forty samples (80%) consisted of target
percentages above 25%.
All 40 samples tested to date have received passing results
with our research qPCR method. For the three 0% samples
from 3 separate surveys, our qPCRmethod gave a result of 0%
for each sample while the STR PCR method gave a result
other than 0% in 14 instances. For the three 100% samples
from 3 separate surveys, our qPCR method gave a result of
100% for each samplewhile the STR PCRmethod gave a result
other than 100% in 10 instances.
It is not until recently (2012), that more than 1 or 2 testing
sites in the ASHI proﬁciency testing program have used
a qPCRmethod. The last ASHI survey of 2012 and the ﬁrst and
current UK NEQAS trial of the 2012-2013 schedule both
included 4 sites using qPCR. The qPCR method is a valuable
tool capable of studying chimerism far below the levels
attained by STR PCR (e.g. microchimerism < 1%). As the
number of sites using qPCR potentially increases, proﬁciency
testing organizations should include lower percentage
samples in order to adequately test the lower sensitivities
attainable with the qPCR method.
While ASHI participation began in 2006, it was not until 2010
that speciﬁc mention of our qPCR approach appeared in the
summary report. In the latest ASHI survey (2012 EMO-2), it
was recognized in the summary report that both conven-
tional (STR PCR) and qPCR assays can be used successfully
based on the comparable performance of the methods. Six
years of proﬁciency testing participation lends concrete
evidence that our research qPCR method is a viable alter-
native to the STR PCR approach offering unmatched sensi-
tivity while maintaining high accuracy and reproducibility
with low to high percentage samples.293
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Background: Respiratory syncytial virus (RSV) is a poten-
tially life threatening infection in allogeneic stem cell
transplant (Allo) recipients. Viral respiratory tract infections
have also been implicated in bronchiolitis obliterans (BO)
and other post Allo non-infectious pulmonary complications
(NIPCs). Since 2000, we have treated RSV infections in Allo
patients (pts) in a standardized manner with pre-established
criteria. We sought to determine survival of such uniformly
treated pts and to ascertain their risk of subsequent NIPCs.
Methods: Allo pts were systematically tested for RSV if they
presented with evidence of lower respiratory tract infection
or upper respiratory tract symptoms and predeﬁned risk
factors for RSV pneumonia. Pts received inhaled ribavirin 2 g
q8h  15 doses and standard IVIG 500 mg/kg/day  4 days
(d) if they exhibited any of the following features: 1) neu-
tropenia, 2) pneumonia, 3) active treatment for GVHD. Data
from 1/00 to 6/12 were collected retrospectively and ana-
lysed on an “intent-to-treat” basis.
Results: We present the ﬁrst 32 pts; their characteristics are
shown in Table 1. Of those with RSV pneumonia, one died 17
d after diagnosis (case fatality rate 6.3%; 95%CI: 0.2-30.2%)
after receiving partial treatment in the context of palliative
care for relapsed leukemia. In total, 13 pts died (40.6%; 95%
CI: 23.7-59.4%). Causes of death other than RSV included
GVHD (n¼4), relapse (n¼5), fungal and bacterial
pneumonia (n¼2), ARDS (n¼1) and other (n¼1). Median OS
from RSV infection was 53 months (m) (95%CI: 22 m-not
reached). Four pts had been diagnosed with BO 9 to 251
d prior to RSV. Among the 28 at risk for developing BO, the
incidence was 0% (95%CI: 0-12.3%). One was diagnosed
with cryptogenic organizing pneumonia 36 d after RSV
(3.4%; 95%CI: 0-18.3%).
Abstracts / Biol Blood Marrow Transplant 19 (2013) S257eS278 S259Conclusion: We observed an extremely low RSV pneumonia
fatality rate in contrast to that reported in the literature.
Perhaps due to strict control of nosocomial transmission, our
cohort tended to contract RSV late, which might account for
better outcomes. Our low incidence of NIPCs is intriguing,
and could be biased by the fact that 66% of our cohort was on
 2 immunosuppressors. Our ﬁndings support prompt
treatment of high-risk patients with inhaled ribavirin/IVIG to
diminish early RSV-related mortality and morbidity.Figure 1. Bacterial foodborne infections among post-transplant HCT patients
by year294
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Background: Diarrhea, abdominal pain and fever are
common among patients undergoing hematopoietic stem
cell transplant (HCT), but such symptoms are also typical
with foodborne infections. The burden of disease caused by
foodborne infections in patients undergoing HCT is
unknown. We sought to describe the incidence of post-
transplant bacterial foodborne infections in a single-center
population of HCT recipients.
Methods: We reviewed all patients who received a HCT at
the Fred Hutchinson Cancer Research Center in Seattle, WA
from 2001 to 2011. Data were collected retrospectively using
center databases, which include information from trans-
plant, on-site examinations, outside records, and collected
laboratory data. Patients were considered to have a bacterial
foodborne illness if Campylobacter jejuni/coli, Salmonella,
Shigella, Yersinia or Listeria species were isolated in culture;
patients with evidence of non-foodborne origin for infection
were excluded. All post-transplant events were classiﬁed as
early ( 100 days post-transplant) or late (>100 days).
Results: A total of 18/4404 (0.4%) patients developed a post-
transplant bacterial foodborne illness (Figure 1). Patients had
a mean age at infection of 45.8 years (range 1 e 68), and the
majority were adults18 years of age (n¼14 [78%]) and male
gender (n¼13, [72%]). Most cases occurred in patients who
had undergone an allogeneic transplant (n¼12 [67%]).
These infectious episodes occurred at a median of 87.5 days
after transplant (IQR 19, 367). The overall incidence rate
post-transplant was 0.34 per 100,000 patient days, and 1.9
per 100,000 in the early post-transplant period. Bacterial
foodborne infections occurred evenly between the early
and late periods (n¼9 early, n¼9 late). The most frequent
pathogen detected was Campylobacter (n¼9 [50 %])
followed by Salmonella (n¼5 [28%]), Yersinia (n¼2 [11%])
and Listeria (n¼2 [11%]); no cases of Shigella were
detected. Diagnoses were made in most patients through
positive stool cultures (n¼13 [72%]), while a smaller
proportion were ﬁrst positive through blood cultures (n¼4
[22%]); one patient was positive simultaneously at both
sites. Mortality due to bacterial foodborne illness was not
observed during follow-up.
Conclusions: Our large single-center study indicates that
bacterial foodborne infections were a rare complication
following HCT. These data provide important baseline inci-
dence for future studies evaluating dietary interventions in
HCT patients.295
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Objective: Invasive fungal infections are a cause of mortality
in pediatric allogeneic hematopoietic cell transplantation
(allo-HCT) recipients. Prophylaxis with triazoles present
a challenge in patients with non-malignant disorders due to
pre-HCT risk for organ dysfunction. Micafungin is an echi-
nocandin with activity against Candida and Aspergillus
species. Limited toxicity and drug interactions of micafungin
make this an attractive option. Limited experience has been
reported in pediatric HCT patients with non-malignant
disorders. We report our experience with daily micafungin
antifungal prophylaxis in pediatric allo-HCT patients with
non-malignant disorders.
Methods: A retrospective descriptive analysis of 28 pediatric
patients with a variety of non-malignant disorders undergoing
allo-HCT and prophylaxis with micafungin is provided. The
median age at allo-HCT was 5 years (range, 0.4-11). No patient
had a previous invasive fungal infections, hepatic, or renal
dysfunction except for one patient with hepatic ﬁbrosis. Cyclo-
sporine was used for graft-versus-host disease prophylaxis.
Results: Table 1 provides a summary of results associated
with daily micafungin antifungal prophylaxis. Micafungin
was discontinued in one patient due to liver function test
abnormalities. A baseline elevation in AST, ALT, and
bilirubin was documented in 25%, 39%, and 0% of patients;
respectively. There was a two-fold increase in AST, ALT, and
bilirubin in 60%, 67%, and 85% of patients during
treatment; these decreased on therapy. A similar trend was
noted in renal function. Cyclosporine levels did not
ﬂuctuate signiﬁcantly during therapy.
Conclusion: Daily micafungin prophylaxis is awell-tolerated
method which may prevent fungal infections in pediatric
allo-HCT patients with non-malignant disorders. Further
study of micafungin prophylaxis to evaluate the efﬁcacy of
micafungin in the prevention of fungal infections in pediatric
allo-HCT recipients with non-malignant disorders is needed.
